Clinical Trials

NCT Number: NCT06303713 Phase: PHASE1 Trial Summary: The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether t – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym:

NCT Number: NCT06457919 Phase: PHASE1|PHASE2 Trial Summary: The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center […]

NCT Number: NCT05369000 Phase: clinical trials Trial Summary: This is a phase 1/2a, first-in-human study to evaluate the safety and tolerability of LAVA-1207 in patients with therapy refractory metastatic castration resistant prosta – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Phase 1|Phase 2 Acronym:

NCT Number: NCT05818683 Phase: clinical trials Trial Summary: The purpose of this study is to identify the recommended phase 2 doses (RP2Ds) of JNJ-78278343 with cetrelimab (JNJ-63723283) in Part 1 (dose escalation) and to determine safety at the RP2D(s) in Part – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Phase 1 Acronym:

NCT Number: NCT06397703 Phase: PHASE3 Trial Summary: For this proposed Phase III study, unfavorable intermediate risk prostate cancer patients will be randomized to receive 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NYU Langone Health Acronym:

NCT Number: NCT06398639 Phase: EARLY_PHASE1 Trial Summary: The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man’s risk of cancer, together – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Alabama at Birmingham […]

NCT Number: NCT06343077 Phase: PHASE2 Trial Summary: This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT05398302 Phase: PHASE1 Trial Summary: This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): 858 Therapeutics, Inc. Acronym:

NCT Number: NCT05546268 Phase: PHASE1|PHASE2 Trial Summary: This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high- – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT06302595 Phase: NA Trial Summary: This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibi – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Brigham and Women’s Hospital […]